<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664829</url>
  </required_header>
  <id_info>
    <org_study_id>BEXMET</org_study_id>
    <nct_id>NCT04664829</nct_id>
  </id_info>
  <brief_title>The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC</brief_title>
  <official_title>Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells From a Mesenchymal-Like to an Epithelial-Like Phenotype</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Medical Research Council (NMRC), Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Centre, Singapore</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Triple-negative breast cancer (TNBC) is biologically aggressive and has limited systemic&#xD;
      treatment options, often compounded by treatment resistance.&#xD;
&#xD;
      Cell state transitions, e.g. epithelial-to-mesenchymal transition (EMT) govern cancer cell&#xD;
      behaviour.&#xD;
&#xD;
      The investigators hypothesize that by inducing change in cell state change, TNBC cells that&#xD;
      have manifested taxane-resistance will be more sensitized to subsequent chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumour transcriptome by RNA sequencing</measure>
    <time_frame>From time of first biopsy before the start of treatment, to disease progression, up to 2 years</time_frame>
    <description>To characterize the changes in tumour transcriptome upon treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumour protein profile by multiplex immunohistochemistry</measure>
    <time_frame>From time of first biopsy before the start of study treatment, to disease progression, up to 2 years</time_frame>
    <description>To characterize the changes in tumour protein profile upon treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidences of treatment related adverse events</measure>
    <time_frame>From time of start of study treatment, to 28 days after last dose of study treatment, up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Metastatic Triple-Negative Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Bexarotene and Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bexarotene</intervention_name>
    <description>Administered orally once a day. Starting dosage: 200mg/m^2</description>
    <arm_group_label>Bexarotene and Capecitabine</arm_group_label>
    <other_name>Targretin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Administered orally twice a day. Dosage: 1000mg/m^2</description>
    <arm_group_label>Bexarotene and Capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically or cytologically proven metastatic TNBC&#xD;
&#xD;
          -  Patients whose TNBC has progressed after prior taxane therapy in the metastatic&#xD;
             setting, and have not received Capecitabine or 5-fluorouracil&#xD;
&#xD;
          -  Females aged 21 years and older&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Life expectancy greater than three months&#xD;
&#xD;
          -  Patients have normal organ and marrow function&#xD;
&#xD;
          -  Site(s) of disease amenable to serial bedside biopsies before, during and after study&#xD;
             treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous palliative radiotherapy to potentially biopsy-able lesion&#xD;
&#xD;
          -  Active symptomatic central nervous system (CNS) metastases&#xD;
&#xD;
          -  Spinal cord compression not definitively treated with surgery and/or radiation&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, ascites requiring recurrent&#xD;
             drainage procedures&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elaine Lim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elaine Lim, MD</last_name>
    <phone>6436 8000</phone>
    <email>elaine.lim.hsuen@singhealth.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169690</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bexarotene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Bexarotene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

